Walleye Capital LLC Buys Shares of 193,709 Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Walleye Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 193,709 shares of the company's stock, valued at approximately $587,000. Walleye Capital LLC owned 0.27% of Zentalis Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Prudential Financial Inc. acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $39,000. Cerity Partners LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $40,000. Ieq Capital LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $46,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $53,000. Finally, Meriwether Wealth & Planning LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $66,000.

Insiders Place Their Bets

In related news, insider Ingmar Bruns purchased 20,000 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was acquired at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the purchase, the insider now owns 36,629 shares in the company, valued at approximately $83,514.12. This represents a 120.27 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jan Skvarka purchased 60,000 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $1.72 per share, with a total value of $103,200.00. Following the purchase, the director now owns 149,551 shares of the company's stock, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company's stock.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL traded down $0.01 during mid-day trading on Monday, hitting $1.42. The stock had a trading volume of 542,549 shares, compared to its average volume of 1,547,366. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $13.24. The stock has a market cap of $101.97 million, a price-to-earnings ratio of -0.57 and a beta of 1.80. The company's 50 day simple moving average is $1.64 and its 200 day simple moving average is $2.49.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter. As a group, equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Analyst Ratings Changes

ZNTL has been the subject of several research reports. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. UBS Group lowered their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Finally, Wedbush reiterated a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $8.24.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.